1.20
price up icon2.56%   0.03
after-market After Hours: 1.20
loading

Mira Pharmaceuticals Inc Stock (MIRA) Latest News

pulisher
Mar 14, 2025

Mira Pharmaceuticals expands pain management pipeline By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 13, 2025

Mira Pharmaceuticals Develops Topical Formulation of Ketamir-2 for Pain Relief -March 13, 2025 at 09:30 am EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Mira Pharmaceuticals succesfully develops topical version of its therapy for localized neuropathic and inflammatory pain - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Mira Pharmaceuticals expands pain management pipeline - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain - Weatherford Democrat

Mar 13, 2025
pulisher
Mar 13, 2025

Revolutionary Topical Pain Treatment: MIRA's Ketamir-2 Targets Multiple Pain Conditions - StockTitan

Mar 13, 2025
pulisher
Mar 13, 2025

EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate - Benzinga

Mar 13, 2025
pulisher
Mar 07, 2025

What is Zacks Small Cap’s Forecast for MIRA FY2024 Earnings? - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

Mira Pharmaceuticals begins phase 1 trial for pain treatment By Investing.com - Investing.com Australia

Mar 05, 2025
pulisher
Mar 04, 2025

SponsoredImpartialComprehensive - Research Tree

Mar 04, 2025
pulisher
Mar 04, 2025

Urgent Boots paracetamol recall after packets found to contain a different drug - AOL

Mar 04, 2025
pulisher
Mar 04, 2025

Mira Pharmaceuticals Announces Approval And Initiation Of Phase 1 Clinical Trial For Ketamir-2 In Neuropathic Pain - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Mira Pharmaceuticals begins phase 1 trial for pain treatment - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Mira Pharmaceuticals announces approval, initiation of Phase 1 Ketamir-2 trial - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain - accessnewswire.com

Mar 04, 2025
pulisher
Mar 04, 2025

Can This Novel Ketamine Analog Outperform Gabapentin? MIRA's Neuropathic Pain Drug Enters Clinical Trials - StockTitan

Mar 04, 2025
pulisher
Mar 04, 2025

EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain - Benzinga India

Mar 04, 2025
pulisher
Feb 27, 2025

Tiziana stock jumps 12% on TBI drug study publication - MSN

Feb 27, 2025
pulisher
Feb 25, 2025

A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - AOL

Feb 25, 2025
pulisher
Feb 18, 2025

Mira Murati's new AI startup poaches 20 OpenAI researchers - Reuters

Feb 18, 2025
pulisher
Feb 10, 2025

MediPharm Labs terminates proposed sale of Napanee facility to Kensana Health - Seeking Alpha

Feb 10, 2025
pulisher
Feb 07, 2025

Microstrategy Inc. – 8% PRF PERPETUAL USD 100 – Ser A’s (STRK) Stock: A Week-by-Week Analysis - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Monday.Com Ltd (MNDY) Shares Down Despite Recent Market Volatility - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Mira Pharmaceuticals Inc (MIRA) Stock: Evaluating the Market Performance - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Vanda Pharmaceuticals Inc (VNDA) Shares Rise Despite Market Challenges - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Air Transport Services Group Inc (ATSG) Stock: Evaluating the Market Performance - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Report: OpenAI's ex-CTO, Mira Murati, has recruited OpenAI co-founder John Schulman - Yahoo Finance

Feb 07, 2025
pulisher
Feb 06, 2025

OpenAI cofounder John Schulman is joining Mira Murati’s startup after brief stint at Anthropic - Yahoo Finance

Feb 06, 2025
pulisher
Feb 06, 2025

Kernel and Mira Launch Industry’s First $300M Secured AI API - GlobeNewswire Inc.

Feb 06, 2025
pulisher
Feb 03, 2025

Mira Network Launches $10M Grant Program for AI Builders - EIN News

Feb 03, 2025
pulisher
Feb 02, 2025

Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy? - AOL

Feb 02, 2025
pulisher
Jan 31, 2025

UCalgary researchers to validate Mira Hormone Monitor - Yahoo Finance

Jan 31, 2025
pulisher
Jan 30, 2025

TEVA Stock Drops Over 5% Amid Financial Struggles - GuruFocus.com

Jan 30, 2025
pulisher
Jan 28, 2025

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End - ACCESS Newswire

Jan 28, 2025
pulisher
Jan 27, 2025

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 27, 2025

U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.18% - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 25, 2025

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance - accessnewswire.com

Jan 25, 2025
pulisher
Jan 24, 2025

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 - accessnewswire.com

Jan 24, 2025
pulisher
Jan 24, 2025

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - accessnewswire.com

Jan 24, 2025
pulisher
Jan 24, 2025

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 15, 2025

Wealth Enhancement Advisory Services LLC Acquires 6,454 Shares of PPL Co. (NYSE:PPL) - Defense World

Jan 15, 2025
pulisher
Jan 15, 2025

International Assets Investment Management LLC Invests $29,000 in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World

Jan 15, 2025
pulisher
Jan 15, 2025

MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Down 1.7% – Should You Sell? - Defense World

Jan 15, 2025
pulisher
Jan 07, 2025

AMRN Stock Rises Over 5% Amidst Lack of Institutional Ratings - GuruFocus.com

Jan 07, 2025
pulisher
Jan 05, 2025

Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation - Yahoo Finance

Jan 05, 2025
pulisher
Dec 31, 2024

Cocrystal stock plunges 40% on influenza drug update (COCP:NASDAQ) - Seeking Alpha

Dec 31, 2024
pulisher
Dec 30, 2024

Traws stock plunges 43% on financing update (TRAW:NASDAQ) - Seeking Alpha

Dec 30, 2024
pulisher
Dec 23, 2024

Zacks Small Cap Has Pessimistic Outlook of MIRA Q4 Earnings - Defense World

Dec 23, 2024
pulisher
Dec 22, 2024

Mira Pharmaceuticals appoints new accounting firm By Investing.com - Investing.com South Africa

Dec 22, 2024
pulisher
Dec 21, 2024

Mira Pharmaceuticals appoints new accounting firm - Investing.com

Dec 21, 2024
pulisher
Dec 21, 2024

Why Wall Street Expects This Growth Stock To Soar 99% In 2025 - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

StatementProposed Amendments To The Air Passenger Protection Regulations - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

Should You Buy Joby Aviation Stock While It's Below $10? - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

C3.ai Stock: Buy, Sell, Or Steer Clear? - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

Is Xcel Energy Stock Underperforming The Nasdaq? - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

2 Fantastic Beaten-Down Growth Stocks Down 35% And 21% To Buy - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

Missed Out on Nvidia: 1 No-Brainer Artificial Intelligence (AI) Stock to Buy Before It Crushes the Market in 2025, and Beyond - Barchart

Dec 21, 2024
pulisher
Dec 21, 2024

MIRA Pharmaceuticals Submits IND for Ketamir-2, Targeting Unmet Needs in Neuropathic Pain Treatment - Barchart

Dec 21, 2024
$107.51
price down icon 2.47%
drug_manufacturers_general SNY
$58.60
price down icon 0.86%
drug_manufacturers_general PFE
$26.21
price down icon 0.38%
$315.75
price down icon 0.91%
drug_manufacturers_general NVS
$111.56
price down icon 0.59%
drug_manufacturers_general MRK
$94.02
price down icon 0.74%
Cap:     |  Volume (24h):